Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 16/20 | 0.83 |
| ▸ | KDR | P35968 | 9/20 | 0.83 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.83 |
| ▸ | BRAF | P15056 | 4/20 | 0.83 |
| ▸ | KIT | P10721 | 12/20 | 0.44 |
| ▸ | SRC | P12931 | 11/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466600 | 0.91 | MAPK14 (1.00) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL4773648 | 0.88 | LCK (0.66) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL11889435 | 0.81 | LCK (0.81) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL4769643 | 0.80 | MAPK14 (0.80) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL4791329 | 0.79 | LCK (0.79) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL11889112 | 0.78 | LCK (0.54) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL2263061 | 0.77 | LCK (0.76) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL4793655 | 0.77 | TNKS (0.55) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL11889207 | 0.76 | LCK (0.58) | LCKKDRMAPK14BRAFKIT | |
| SCHEMBL11888995 | 0.70 | BRAF (0.68) | LCKKDRMAPK14BRAFTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | claimed |
| EP-1976836-A2 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | Amgen Inc. (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | claimed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | claimed |
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | LCK 392/4885KDR 578/4885MAPK14 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.